Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1)

  Measured over: Up to 28 days after the first dose of study treatment

• Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1)

  Measured over: Time of first dose up to 30 days after last dose

• Progression-Free Survival (PFS) (Part 2)

  Measured over: From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

Changes Tremor has spotted